Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycinsensitive were sensitive to MLN0128 in vitro. MLN0128 inhibite...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Hassan, Burhan, Akcakanat, Argun, Sangai, Takafumi, Evans, Kurt W., Adkins, Farrell, Eterovic, Agda Karina, Zhao, Hao, Chen, Ken, Chen, Huiqin, Do, Kim-Anh, Xie, Shelly M., Holder, Ashley M., Naing, Aung, Mills, Gordon B., Meric-Bernstam, Funda
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226703/
https://ncbi.nlm.nih.gov/pubmed/25261369
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki